🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My third #MCCRworkshop ends as usual: sleep-deprived, exhausted, but exhilarated after learning so much from the trials of my PDG10. I could not be prouder! It was great to share my experience as an Follow us on Bluesky @ICR-CTSU cancer trial statistician!

A quick summary of our retrospective analysis of HER2 in bladder cancer from from our group Gopa Iyer Neil Shah Hikmat Al Ahmadie Memorial Sloan Kettering Cancer Center Presented at ASCO #GU24 from VJ Oncology Correlations between HER2 and PD-L1 expression in bladder ca... youtu.be/ziEnuvdnguk?si…

Congratulations Olivia Prior 🌸 Raquel Perez-Lopez Kinga Bernatowicz Marta Ligero et al - this is an important contribution towards developing robust approaches for #cancer microstructure assessment in real-world clinical settings. Proud to be part of this!

Next Wednesday PCF Science is organising a webinar about current use and future prospects for PARPi in #prostatecancer - looking forward to this discussion! If you want to join, the link is below

Our latest paper is now out in European Urology -A prospective study of whole-body MRI in mCRPC with bone mets: the IPROMET clinical trial. Work with Raquel Perez-Lopez Radiomics Group authors.elsevier.com/a/1ilku_6tuN-i…

Identifican nuevos biomarcadores de imagen para predecir la respuesta al tratamiento en pacientes con cáncer de próstata con metástasis óseas 🗞️ Los resultados del estudio #iPROMET se han publicado en European Urology ➡️  linke.to/iPROMETCASTVHIO

#clinicalresearch #prostatecancer #genitourinarydisease

Amazing experience in #ASCO24 at the Poster Session-GU Cancer. We presented our work evaluating the HRR status in mPC by NGS and the functional RAD51-IF assay.🧬💻🔬 Abstract 5024 Prostate Cancer Translational Research Team 🔝🚀 Vall d’Hebron Institute of Oncology (VHIO) Vall d'Hebron Joaquin Mateo Thank you to all!!

ESMO - Eur. Oncology Recommendations for clinical reporting of genomics - now published in Annals of Oncology. We're aiming to advance rational, evidence-based use of genomics in patient care and harmonize biomarker interpretation in cancer treatment annalsofoncology.org/article/S0923-…

A joint effort with Joaquin Mateo, highlighting the clinical relevance, emerging molecular distinctive features and therapeutic progress in the most aggresive clinical manifestation of prostate cancer. Asociación Española Contra el Cáncer CIBERONC ASEICA sciencedirect.com/science/articl…

📢 #mHNPC, a distinct biological entity? Read our last #review!!! Thanks to Joaquin Mateo and ArkaitzCarracedoLAB sciencedirect.com/science/articl…

Excited to share the findings from the multicenter real-world ARON-3 study, now published in European Urology Oncology! 📌 The analysis highlights that apalutamide in mHSPC remains a safe and effective treatment in real-world practice. 📖 Full article: lnkd.in/d8JJPUPW

Our review on the current state of PARPi development for #prostatecancer is now out in European Urology Oncology - led by Francesca Zacchi + help from several experts in the field sciencedirect.com/science/articl…

Excited to share our publication in European Urology Oncology. It has been an honor to collaborate with leading experts in prostate cancer, and I am incredibly grateful for the exceptional mentorship from Dr. Joaquin Mateo. Full article: lnkd.in/gzkxxniD

Back from the magic Genève for an amazing #ESMOIO congress with my super ex-colleagues 🔝

🎙️ CALL FOR PAPERS on SPECIAL RESEARCH TOPIC in FRONTIERS IN ONCOLOGY 🧬 Research Topic: Prostate Cancer Senescence: Therapeutic Challenges and Opportunities. Manuscript Summary Submission Deadline 28Feb2025 Manuscript Submission Deadline 30June2025 Link: lnkd.in/dFCj5iZH

Our latest paper is out in Cell Reports Medicine - Functional RAD51-IF to detect HRR defects in #ProstateCancer - exploring correlations between HRR mutations, HRD scores, and RAD51-IF in mPC biopsies #OpenAccess #CancerResearch cell.com/cell-reports-m…

🎉I am excited to share our latest publication in Frontiers in Oncology, AvePem Study, a real word study that compare 1L maintainance Avelumab vs 2L Pembrolizumab frontiersin.org/journals/oncol…

Grateful to be involved! Thanks to @AnitaBorsati and her group! onlinelibrary.wiley.com/doi/full/10.11…

European Urology Oncology (online 28 April 2025). "Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study". sciencedirect.com/science/articl…